Transgene raises funds to expand vaccine facilities
French biopharmaceutical company Transgene has raised Euro 130m in capital, some of which will be used for increasing ithe company's cGMP facilities in Strasbourg for production of its lead therapeutic vaccine candidate TG 4001.
French biopharmaceutical company Transgene has raised Euro 130m in capital, some of which will be used for increasing ithe company's cGMP facilities in Strasbourg for production of its lead therapeutic vaccine candidate TG 4001.
The antigen specific therapeutic vaccine TG 4001 for treating cervical cancer has completed Phase II studies and is due to enter into Phase III studies in early 2008. In April this year, Roche signed an agreement to help develop and commercialise the vaccine.
The drug is designed to treat precancerous cervical lesions in 20 -35 year old patients that have contracted the Human Papilloma Virus 16.
The company also plans to put more of its drug pipeline through clinical trials, including drug candidate TG1042 for treating cutaneous B-Cell Lymphoma. It expects the first interim results for the phase 11b trials in the last quarter of 2007.
At the beginning of the year, the company also began phase 1 trials of its vaccine for chronic hepatits C and it expects results at the end of the year.